Accelerated Treatment of Depressive Patients With tDCS
Recruiting · NCT07444242 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Regensburg
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
A randomized, controlled three-arm study is planned to investigate the effectiveness and feasibility of an accelerated home-based tDCS application (3 weeks of transcranial direct current stimulation at home, twice daily). A total of 30 patients with depression (10 per group), who are currently not taking and have no history of taking antidepressant medication, will be randomly assigned to either an active tDCS condition, a sham (placebo) tDCS condition, or a waitlist control group. The latter two groups will receive active tDCS treatment after completion of the control phase. This study represents a continuation of the pilot study GSUND DAHOAM (Ethics approval: 20-2091-101; Dragon et al., 2024).
Who can take part
Inclusion criteria
- Sex: female, male, non-binary
- Age: 18-70 years
- Diagnosis of depression: no current or past psychiatric medication (current episode and history)
- Provision of informed consent to participate
- Sufficient proficiency in the German language
Exclusion criteria
- Presence of contraindications for tDCS (e.g., electrical implants or metallic objects in the body such as a cardiac pacemaker or insulin pump, dermatological conditions affecting the scalp)
- Neurological disorders (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformations, or a history of severe head injury)
- Participation in another clinical trial on depression within the 3 months prior to treatment initiation
- Pregnancy or breastfeeding
Where it is running
1 location listed.
- Psychiatry and Psychotherapy, Center of Neuromodulation / TMS, University Regensburg - Regensburg, Bavaria, Germany